

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## **Single Technology Appraisal**


Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer ID6168

#### Provisional Stakeholder List

montatoro (no right to submit su
nmentators (no right to submit or
eal)
eral
All Wales Therapeutics and Toxicology
Centre
Allied Health Professionals Federation
Board of Community Health Councils in
Vales
British National Formulary
Care Quality Commission
Department of Health, Social Services
and Public Safety for Northern Ireland
lealthcare Improvement Scotland
Medicines and Healthcare products
Regulatory Agency
lational Association of Primary Care
lational Pharmacy Association
IHS Confederation
Scottish Medicines Consortium
Velsh Government
Velsh Health Specialised Services
Committee
sible comparator companies
Bristol Myers Squibb (nivolumab)
lospira UK (cisplatin, gemcitabine)
Ranbaxy UK (gemcitabine)
Sandoz (cisplatin)
Synchrony Pharma (gemcitabine)
Jilon on Ji Hama (gomonabillo)
vant research groups
Cochrane Urology
Genomics England
nstitute of Cancer Research
ARC Clinical Trials Unit
AINO OIIIIIGAI THAIS OHII

Draft stakeholder list for the evaluation of durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer ID6168

Issue date: January 2025



Consultees	Commentators (no right to submit or appeal)
<ul> <li>Cancer Research UK</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Radiologists</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>Society and College of Radiographers</li> <li>UK Clinical Pharmacy Association</li> <li>UK Oncology Nursing Society</li> <li>Urology Foundation</li> </ul> Others <ul> <li>Department of Health and Social Care</li> <li>NHS England</li> </ul>	<ul> <li>National Institute for Health Research</li> <li>Associated Public Health groups</li> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

## **Definitions:**

## Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).


### <u>Commentators</u>

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare

Draft stakeholder list for the evaluation of durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer ID6168

Issue date: January 2025





Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Draft stakeholder list for the evaluation of durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer ID6168